Skip to main content
Clinical Trials/NCT01538992
NCT01538992
Withdrawn
Phase 3

Phase 3 Study of Renal Denervation That Improves Symptoms of Heart Failure and Enhances Life Quality in Advanced Heart Failure

Bursa Postgraduate Hospital1 site in 1 countryApril 2013
ConditionsHeart Failure

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Bursa Postgraduate Hospital
Locations
1
Primary Endpoint
Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events
Status
Withdrawn
Last Updated
12 years ago

Overview

Brief Summary

Sympathetic system has important role occurrence of symptoms in heart failure. Renal denervation that is ablated some of sympathetic nerves is affected pathology of heart failure. This interventional therapy improves symptoms and life quality.

Detailed Description

Primary Outcome Measures: • Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events Secondary Outcome Measures: • Ventricular function,NYHA functional Class, 6 min walking test, biochemical test and Renal function as measured by Glomerular Filtration Rate (GFR) Eligibility Patients population: Volunteers, NYHA Class III-IV heart failure patients. Ages Eligible for Study: 18 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
April 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hasan ARI

Medical Doctor, Cardiology Chief Intern

Bursa Postgraduate Hospital

Eligibility Criteria

Inclusion Criteria

  • Heart Failure patients NYHA Class III or IV
  • Left Ventricular Ejection Function \< 35%
  • GFR \> 45 mL/min/1.73m2
  • Optimal stable medical therapy

Exclusion Criteria

  • Do not eligible renal artery anatomy for treatment as determined by Angiography, and
  • History of prior renal artery intervention
  • Single functioning kidney.
  • Myocardial Infarction, unstable angina pectoris or cerebrovascular Accident within 3 months
  • Systolic BP \< 110mmHG Hospitalisation because of heart failure in last 3 weeks.

Outcomes

Primary Outcomes

Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events

Time Frame: 6 months

Secondary Outcomes

  • • Ventricular function as measured by Echocardiography • NYHA functional Class, 6 min walking test, biochemical test. • Renal function as measured by Glomerular Filtration Rate (GFR)(6 months)

Study Sites (1)

Loading locations...

Similar Trials